STZ Stock Analysis: Constellation Brands | NYSE
Beverages - Brewers | NYSE, USA | Market Cap: 22.080m USD | 12M Return: -23.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 315M
EPS Trend: 18.6%
Qual. Beats: 4
Rev. Trend: -65.3%
Qual. Beats: 3
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Constellation Brands, Inc. (NYSE: STZ) is a multinational alcoholic beverage company that produces, imports, markets, and sells beer, wine, and spirits across the United States, Canada, Mexico, New Zealand, and Italy. Its beer portfolio includes flagship Mexican brands such as Corona Extra and Modelo Especial, while its wine business features labels like Kim Crawford, Robert Mondavi Winery, and The Prisoner Wine Company. The company also offers spirits under brands including Casa Noble, High West, and Nelsons Green Brier.
The company distributes its products through wholesale distributors, retailers, and state alcohol beverage control agencies. Founded in 1945, Constellation Brands is headquartered in Rochester, New York, and trades on the NYSE as a large-cap stock classified within the Consumer Staples sector.
As a major player in the Distillers & Vintners sub-industry, Constellation Brands operates a multi-category beverage model that combines owned production, brand licensing, and import partnerships. Its heavy weighting toward Mexican beer imports-particularly through its longstanding agreement with Grupo Modelos brands-has made it a leading participant in the U.S. beer market by volume.
- Modelo Especial gains share as Hispanic demographics fuel beer demand
- Wine and Spirits divestitures reduce persistent margin drag
- Mexican tariff and peso exposure pressure imported beer margins
| Net Income: 1.82b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -0.99 > 1.0 |
| NWC/Revenue: -3.18% < 20% (prev 2.46%; Δ -5.64% < -1%) |
| CFO/TA 0.12 > 3% & CFO 2.69b > Net Income 1.82b |
| Net Debt (11.1b) to EBITDA (3.31b): 3.35 < 3 |
| Current Ratio: 0.91 > 1.5 & < 3 |
| Outstanding Shares: last quarter (172.4m) vs 12m ago -3.14% < -2% |
| Gross Margin: 52.62% > 18% (prev 51.06%; Δ 1.56% > 0.5%) |
| Asset Turnover: 40.82% > 50% (prev 45.19%; Δ -4.37% > 0%) |
| Interest Coverage Ratio: 8.42 > 6 (EBIT TTM 2.90b / Interest Expense TTM 344.3m) |
| A: -0.01 (Total Current Assets 3.04b - Total Current Liabilities 3.33b) / Total Assets 22.1b |
| B: 0.64 (Retained Earnings 14.1b / Total Assets 22.1b) |
| C: 0.13 (EBIT TTM 2.90b / Avg Total Assets 22.2b) |
| D: 0.61 (Book Value of Equity 8.26b / Total Liabilities 13.6b) |
| Altman-Z'' = 3.50 = A |
| DSRI: 0.99 (Receivables 726.7m/813.3m, Revenue 9.06b/10.1b) |
| GMI: 0.97 (GM 51.06% / 52.62%) |
| AQI: 1.06 (AQ_t 0.48 / AQ_t-1 0.45) |
| SGI: 0.90 (Revenue 9.06b / 10.1b) |
| TATA: -0.04 (NI 1.82b - CFO 2.69b) / TA 22.1b) |
| Beneish M = -3.10 (Cap -4..+1) = AA |
As of July 26, 2026, the stock is trading at USD 130.16 with a total of 1,189,542 shares traded. Over the past week, the price has changed by -2.04%, over one month by -8.99%, over three months by -16.01% and over the past year by -23.88%.
Current recommended Stop Loss: 124.50 (which is 4.3% or 1.3 ATR below the current price).
Constellation Brands has received a consensus analysts rating of 3.96. Therefore, it is recommended to buy STZ.
- StrongBuy: 9
- Buy: 7
- Hold: 10
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 170.7 | 31.1% |
P/E Trailing = 12.5749
P/E Forward = 11.2994
P/S = 2.438
P/B = 2.7323
P/EG = 2.5108
Revenue TTM = 9.06b USD
EBIT TTM = 2.90b USD
EBITDA TTM = 3.31b USD
Long Term Debt = 9.09b USD (from longTermDebt, last quarter)
Short Term Debt = 1.44b USD (from shortTermDebt, last quarter)
Debt = 11.2b USD (from shortLongTermDebtTotal, last quarter) + Leases 634.1m
Net Debt = 11.1b USD (calculated: Debt 11.2b - CCE 96.6m)
Enterprise Value = 33.2b USD (22.1b + Debt 11.2b - CCE 96.6m)
Interest Coverage Ratio = 8.42 (Ebit TTM 2.90b / Interest Expense TTM 344.3m)
EV/FCF = 18.07x (Enterprise Value 33.2b / FCF TTM 1.83b)
FCF Yield = 5.53% (FCF TTM 1.83b / Enterprise Value 33.2b)
FCF Margin = 20.25% (FCF TTM 1.83b / Revenue TTM 9.06b)
Net Margin = 20.14% (Net Income TTM 1.82b / Revenue TTM 9.06b)
Gross Margin = 52.62% ((Revenue TTM 9.06b - Cost of Revenue TTM 4.29b) / Revenue TTM)
Gross Margin QoQ = 54.29% (prev 49.56%)
Tobins Q-Ratio = 1.50 (Enterprise Value 33.2b / Total Assets 22.1b)
Interest Expense / Debt = 3.08% (Interest Expense 344.3m / Debt 11.2b)
Taxrate = 24.60% (621.5m / 2.53b)
NOPAT = 2.18b (EBIT 2.90b * (1 - 24.60%))
Current Ratio = 0.91 (Total Current Assets 3.04b / Total Current Liabilities 3.33b)
Debt / Equity = 1.35 (Debt 11.2b / totalStockholderEquity, last quarter 8.26b)
Debt / EBITDA = 3.35 (Net Debt 11.1b / EBITDA 3.31b)
Debt / FCF = 6.04 (Net Debt 11.1b / FCF TTM 1.83b)
Total Stockholder Equity = 7.89b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.22% (Net Income 1.82b / Total Assets 22.1b)
RoE = 23.13% (Net Income TTM 1.82b / Total Stockholder Equity 7.89b)
RoCE = 17.06% (EBIT 2.90b / Capital Employed (Equity 7.89b + L.T.Debt 9.09b))
RoIC = 10.86% (NOPAT 2.18b / Invested Capital 20.1b)
WACC = 4.94% (E(22.1b)/V(33.2b) * Re(6.26%) + D(11.2b)/V(33.2b) * Rd(3.08%) * (1-Tc(0.25)))
Discount Rate = 6.26% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -98.81 | Cagr: -2.75%
[DCF] Terminal Value 73.75% ; FCFF base≈1.93b ; Y1≈1.75b ; Y5≈1.52b
[DCF] Fair Price = 76.80 (EV 24.2b - Net Debt 11.1b = Equity 13.1b / Shares 170.8m; r=8.35% [WACC [floored]]; 5y FCF grow -11.28% → 2.50% )
EPS Correlation: 18.64 | EPS CAGR: 1.28% | SUE: 1.17 | # QB: 4
Revenue Correlation: -65.25 | Revenue CAGR: -3.03% | SUE: 0.97 | # QB: 3
EPS current Quarter (2026-08-31): EPS=3.61 | Chg30d=-2.77% | Revisions=-61% | Analysts=19
EPS next Quarter (2026-11-30): EPS=2.85 | Chg30d=-3.60% | Revisions=-61% | Analysts=19
EPS current Year (2027-02-28): EPS=11.79 | Chg30d=+0.11% | Revisions=-23% | GrowthEPS=-0.2% | GrowthRev=-0.4%
EPS next Year (2028-02-29): EPS=12.37 | Chg30d=-0.19% | Revisions=-29% | GrowthEPS=+4.9% | GrowthRev=+1.9%
[Analyst] Revisions Ratio: -47% (up=17, down=50)